-
PRAC highlights January 2021
PRAC highlights January 2021
-
PRAC highlights January 2021
PRAC highlights January 2021
At its January meeting, the PRAC concluded evaluation of risk of acute adrenal insufficiency in children when switching to Alkindi.
-
EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
-
EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
AstraZeneca has submitted an application for its COVID-19 vaccine developed with Oxford University. The assessment will proceed under an accelerated timeline.
-
Second COVID-19 vaccine authorised in the EU
Second COVID-19 vaccine authorised in the EU
-
Second COVID-19 vaccine authorised in the EU
Second COVID-19 vaccine authorised in the EU
The European Commission has granted a conditional marketing authorisation for a second vaccine to prevent COVID-19 in the European Union, following EMA's recommendation. It can be used in people from 18 years of age.
-
Development, evaluation and monitoring of COVID-19 vaccines
Development, evaluation and monitoring of COVID-19 vaccines
-
Development, evaluation and monitoring of COVID-19 vaccines
Development, evaluation and monitoring of COVID-19 vaccines
Read about how EMA is ensuring vaccines for COVID-19 meet the highest standards of quality, safety & efficacy while their development and approval is sped up due to the public health emergency.
